| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 145, Issue 6 1719-1726, Copyright © 1990 by American Association of Immunologists
ARTICLES |
GW Cox, BJ Mathieson, SL Giardina and L Varesio
Laboratory of Molecular Immunoregulation, National Cancer Institute- Frederick Cancer Research and Development Center, National Institutes of Health, MD 21702-1201.
This study was designed to examine the expression and function of IL-2R on murine macrophages. We used a model system of murine macrophage cell lines (ANA-1 and GG2EE) that was established by infecting normal murine bone marrow-derived cells with the J2 (v-raf/v-myc) recombinant murine retrovirus. ANA-1 macrophages did not constitutively express detectable levels of mRNA for the p55, IL-2R alpha. However, a brief exposure to IFN-gamma was sufficient to induce IL-2R alpha mRNA in ANA-1 macrophages. Flow cytometric analysis indicated that ANA-1 macrophages expressed low constitutive levels of IL-2R alpha on their cell surface that were augmented after treatment of the cells with IFN-gamma. Affinity binding and cross-linking of [125I]IL-2 to ANA-1 macrophages demonstrated that IL-2R alpha and the p70-75, IL-2R beta were both present on ANA-1 macrophages constitutively. IFN-gamma increased the expression of IL-2R alpha on ANA-1 macrophages but did not increase the expression of IL-2R beta on these macrophages. Although IL-2 alone did not induce the tumoricidal activity of ANA-1 macrophages, IL-2 acted synergistically with IFN-gamma to induce macrophage tumoricidal activity. These data demonstrate the expression of IL-2R on murine macrophage cell lines and establish the role of IL-2 as a costimulator of macrophage-mediated tumoricidal activity.
This article has been cited by other articles:
|
|
 |
|
  C. Quiniou, P. Sapieha, I. Lahaie, X. Hou, S. Brault, M. Beauchamp, M. Leduc, L. Rihakova, J.-S. Joyal, S. Nadeau, et al. Development of a Novel Noncompetitive Antagonist of IL-1 Receptor J. Immunol., May 15, 2008; 180(10): 6977 - 6987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Nardelli, T. F. Warner, S. M. Callister, and R. F. Schell Anti-CD25 Antibody Treatment of Mice Vaccinated and Challenged with Borrelia spp. Does Not Exacerbate Arthritis but Inhibits Borreliacidal Antibody Production. Clin. Vaccine Immunol., August 1, 2006; 13(8): 884 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Vodovotz, L. Chesler, H. Chong, S.-J. Kim, J. T. Simpson, W. DeGraff, G. W. Cox, A. B. Roberts, D. A. Wink, and M. H. Barcellos-Hoff Regulation of Transforming Growth Factor {beta}1 by Nitric Oxide Cancer Res., May 1, 1999; 59(9): 2142 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Le, R. Daniel, S.-W. Chung, A. D. Kang, T. K. Eisenstein, B. M. Sultzer, H. Simpkins, and P. M. C. Wong Involvement of C-Abl Tyrosine Kinase in Lipopolysaccharide- Induced Macrophage Activation J. Immunol., April 1, 1998; 160(7): 3330 - 3336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Cox, L. S. Taylor, J. D. Willis, G. Melillo, R. L. White III, S. K. Anderson, and J.-J. Lin Molecular Cloning and Characterization of a Novel Mouse Macrophage Gene That Encodes a Nuclear Protein Comprising Polyglutamine Repeats and Interspersing Histidines J. Biol. Chem., October 11, 1996; 271(41): 25515 - 25523. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
